“SGLT2 Inhibitors in Elderly and Frail CKM Patients Consistent Benefit across Age and Frailty, With No Excess Hypoglycaemia”. Diabzen 4, no. 15 (July 7, 2026): 28–29. Accessed November 4, 2026. https://www.thediabzen.com/index.php/d/article/view/57.